Guangdong Hybribio Biotech Co Ltd

Hybribio announced on October 11 that its wholly-owned subsidiary, Chaozhou Hybribio Biochemistry Co., Ltd., has recently obtained the Medical Device Registration Certificate of the People's Republic of China for in vitro diagnostic reagents issued by the National Medical Products Administration. The registered product is a vaginal microorganism nucleic acid detection kit using PCR-fluorescent probe method, valid from October 9, 2026 to October 8, 2031, primarily for the in vitro qualitative detection of nucleic acids of Trichomonas vaginalis, Gardnerella vaginalis, and Candida albicans in vaginal secretions. The company stated that obtaining this registration certificate will further improve its product portfolio for reproductive tract infection testing, meet diversified market demand, and support its goal of becoming a leading enterprise in nucleic acid molecular diagnostics. The announcement also cautioned that actual sales and profit contribution of the approved product are subject to factors such as market promotion effectiveness and actual demand, and remain uncertain; the company is currently unable to predict the impact on its future operating results. In the interim period of 2026, Hybribio achieved revenue of 300 million yuan and net profit attributable to the parent company of 31.26 million yuan.

Kaipu Bio's wholly owned subsidiary Chaozhou Kaipu Biochemistry Company Limited has obtained a Class III medical device registration certificate issued by the National Medical Products Administration for its Chikungunya virus and dengue virus nucleic acid detection kit using fluorescent PCR. The registration certificate number is 20263401806, valid until August 30, 2031. The kit is used for in vitro qualitative detection of nucleic acids from both viruses in human serum or plasma samples, enabling simultaneous detection of two pathogens from a single sample, with the entire process completed within 70 minutes. Dengue fever and chikungunya are both acute infectious diseases transmitted by mosquitoes, with similar early symptoms. In April 2026, the National Disease Control and Prevention Administration included chikungunya in the management of Class B infectious diseases, requiring joint surveillance, testing, and prevention and control for both diseases. The company stated that this product enhances its product portfolio, aligns with its Nucleic Acid 99 strategic plan, and will have a positive impact on future operations, though actual sales and profit contributions remain uncertain.

Kaipu Bio disclosed its 2026 semi-annual report. In the first half, net profit attributable to shareholders of the listed company was 31.2621 million yuan, compared with a loss of 89.5914 million yuan in the same period last year, turning from loss to profit year-on-year. The company achieved total operating revenue of 300 million yuan in the first half, down 4.74 percent year-on-year, with basic earnings per share of 0.0484 yuan. During the reporting period, the company reversed credit impairment losses of 30.4456 million yuan and made asset impairment provisions of 437,500 yuan. Credit impairment losses and asset impairment losses decreased by 88.0096 million yuan and 10.4566 million yuan respectively compared with the same period last year. Combined with factors such as increased exchange gains and reduced selling expenses in the current period, these jointly drove net profit attributable to shareholders of the listed company to increase by 121 million yuan compared with the same period last year.